Loading...
•
Mar 31, 2021
CRISPR Therapeutics Q1 2021 Earnings Report
CRISPR Therapeutics reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
CRISPR Therapeutics reported a net loss of $113.2 million for the first quarter of 2021, compared to a net loss of $69.7 million for the first quarter of 2020. Total collaboration revenue was $0.2 million for the first quarter of 2021, consistent with the first quarter of 2020. Cash, cash equivalents and marketable securities were $1,806.2 million as of March 31, 2021, compared to $1,690.3 million as of December 31, 2020.
Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)
More than 30 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021
Enrollment ongoing in CTX110™, CTX120™ and CTX130™ clinical trials
Revised agreement with Vertex for CTX001 streamlines operations and allows further investment in innovation
Revenue by Segment
Forward Guidance
The company expects to disclose data on multiple programs in 2021 and is continuing to execute on its earlier stage pipeline, looking forward to bringing regenerative medicine and in vivo programs to the clinic.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...